CStone Pharmaceuticals receives positive CHMP opinion for Sugemalimab in NSCLC treatment
CStone Pharmaceuticals (HKEX: 2616), a leading innovation-driven biopharmaceutical company from China, announced a significant milestone with the Committee for Medicinal Products for Human Use (CHMP) ... Read More
Affimed N.V. reports promising results from AFM24-102 trial in NSCLC
Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, has released compelling clinical data from its ongoing AFM24-102 study, showcasing significant advances in treating non-small cell ... Read More
CStone’s sugemalimab gains CHMP recommendation for NSCLC treatment
CStone Pharmaceuticals has reached a pivotal milestone in its global strategy, with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ... Read More
AstraZeneca’s Imfinzi garners positive opinion from CHMP for NSCLC treatment
AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a ... Read More
AstraZeneca’s Tagrisso secures FDA breakthrough therapy designation for first-line treatment of NSCLC
AstraZeneca has achieved a significant milestone with its lung cancer drug, Tagrisso (osimertinib), which has recently been granted the Breakthrough Therapy Designation (BTD) by the ... Read More